ITRMF.US Iterum Therapeutics plc

Healthcare Biotechnology USA Stocks
0.0000 USD
Close of Nov 15, 2026
Market cap
USD 532.00
P/E
-
P/B
0.43x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2025.

Is ITRMF.US undervalued?

Graham number

The Graham number of Iterum Therapeutics plc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Iterum Therapeutics plc fundamental analysis

No fundamental analysis for Iterum Therapeutics plc yet.

Iterum Therapeutics plc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Iterum Therapeutics plc

Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developi…

Full company profile